Literature DB >> 6738827

Sulpiride isomers exhibit reversed stereospecificity for D-1 and D-2 dopamine receptors in the CNS.

S E Leff, A Chen, I Creese.   

Abstract

We have investigated the stereospecificity of the interaction of (-) and (+)sulpiride with [3H]cis-flupentixol and [3H]spiperone binding to D-1 and D-2 dopamine receptors respectively in rat striatum. Both isomers of sulpiride compete more potently at D-2 vs. D-1 dopamine receptors. (-)Sulpiride is 50-fold more potent than (+)sulpiride in blocking D-2 receptors, while (+)sulpiride is 3-fold more potent than (-)sulpiride at D-1 receptors. This reversed stereospecificity of sulpiride interactions with CNS D-1 and D-2 dopamine receptors is similar to the stereospecificity of sulpiride interactions at DA1 and DA2 dopamine receptors in peripheral vascular beds.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6738827     DOI: 10.1016/0028-3908(84)90034-0

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  3 in total

1.  Human dopamine receptor subtypes--in vitro binding analysis using 3H-SCH 23390 and 3H-raclopride.

Authors:  H Hall; L Farde; G Sedvall
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

2.  Discriminative stimulus properties of the atypical antipsychotic amisulpride: comparison to its isomers and to other benzamide derivatives, antipsychotic, antidepressant, and antianxiety drugs in C57BL/6 mice.

Authors:  Timothy J Donahue; Todd M Hillhouse; Kevin A Webster; Richard Young; Eliseu O De Oliveira; Joseph H Porter
Journal:  Psychopharmacology (Berl)       Date:  2017-09-18       Impact factor: 4.530

3.  Dopamine receptor-mediated spinal antinociception in the normal and haloperidol pretreated rat: effects of sulpiride and SCH 23390.

Authors:  S Barasi; M M Ben-Sreti; A L Clatworthy; K N Duggal; J P Gonzalez; J Robertson; K F Rooney; R D Sewell
Journal:  Br J Pharmacol       Date:  1987-01       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.